Background: The precise role of the Akt kinase in NF-kB induction by the TCR and CD28 is still unclear.

Results: We have found that Akt makes a quantitative contribution to NF-kB induction in T cells, selectively impacting a subset of downstream genes.

Conclusion: Although Akt is not a canonical member of the NF-kB pathway, it can modulate NF-kB signaling and transcription.

Significance: These findings may open the way to more selective modulation of NF-kB-dependent pathways.

SUMMARY

Activation of the NF-kB signaling pathway is critical for leukocyte activation and development. Although previous studies suggested a role for the Akt kinase in coupling the T cell antigen receptor and CD28 to NF-kB activation in T cells, the nature of the role of Akt in this pathway is still unclear. Using a targeted gene profiling approach, we found that a subset of NF-kB-dependent genes required Akt for optimal upregulation during T cell activation. The selective effects of Akt were manifest at the level of mRNA transcription and p65/RelA binding to upstream promoters, and appear to be due to altered formation of the Carma1/Bcl10 complex. The pro-inflammatory cytokine TNF-α was found to be particularly sensitive to Akt inhibition or knock-down, including in primary human blood T cells and a murine model of rheumatoid arthritis. Our findings are consistent with a hierarchy in the expression of NF-kB-dependent genes, controlled by the strength and/or duration of NF-kB signaling. More broadly, our results suggest that defining the more graded effects of signaling, such as those demonstrated here for Akt and the NF-kB pathway, is important to understanding how cells can fine tune signaling responses for optimal sensitivity and specificity.

The proto-oncogenic kinase known as Akt (or PKB) is a serine/threonine kinase activated downstream of the lipid kinase PI-3 kinase, which is recruited to ligated growth factor and antigen receptors. Dysregulation of the Akt pathway has been demonstrated in numerous cancers, including some leukemias and lymphomas (1,2), and many downstream targets for Akt have been described (3). Previous reports from our lab and others demonstrated that one downstream effect of Akt activation is NF-kB-dependent transcription (4), but it is still not known what role NF-kB plays in Akt dependent biological processes overall. Most previous studies, including our own, relied on gain-of-function approaches to show that Akt can be sufficient to upregulate NF-kB-dependent transcription. Thus, the degree to which Akt is actually necessary for NF-kB induction during T cell activation is not clear and, indeed, controversial.

NF-kB family transcription factors reside in the cytoplasm of unstimulated cells as homo- or heterodimers in complexes with the IkB proteins. Upon stimulation, phosphorylation by IKK triggers IkB degradation, which promotes NF-kB factor translocation to the nucleus, followed by their binding to - and activation of - transcription from numerous genes (5). However, the regulation of gene transcription by NF-kB is more complex than this simple model suggests, and it is now clear that multiple levels of regulation exist to yield the known stimulation- and cell type-specific patterns of NF-kB gene expression (6). For example, differences in the magnitude, duration and/or periodicity of NF-kB activation have been shown to contribute to the upregulation of different subsets of NF-kB-dependent genes by different receptors (7-11).

Recently, the development of more potent and selective small molecule inhibitors of Akt has facilitated the study of Akt function both in vitro and in vivo, although these have mostly been explored as possible cancer therapies (12,13). Here we have employed the compound Akti 1/2, an
allosteric inhibitor that stabilizes the inactive conformation of both Akt1 and Akt2, but not Akt3 (14). We previously showed that this compound is an effective inhibitor of Akt activation in T cells, at least under conditions of short-term stimulation (4). We also used the complementary approach of knocking down Akt1 and Akt2 with siRNA. In this study, using targeted gene array analysis, we analyzed the program of NF-κB-dependent gene-expression induced during T cell activation and established a subset of genes that requires Akt for their upregulation. Our findings demonstrate that Akt fine-tunes NF-κB-dependent transcription by the TCR and CD28, with only a subset of genes sensitive to the loss of Akt activity. Importantly, we provide mechanistic evidence that the difference between Akt-sensitive and –insensitive NF-κB target genes is due to quantitative effects of Akt on NF-κB induction. Finally, using this approach, we have identified and validated the pro-inflammatory cytokine TNF-α as a particularly sensitive target for Akt inhibition in T cells.

**EXPERIMENTAL PROCEDURES**

*Antibodies and reagents* - Anti-human CD3ε and CD28 were from BioLegend (San Diego, CA). Biotin-anti-mCD28 (37.51) and biotin-anti-mCD3ε (145-2C11) were from BD Biosciences (San Jose, CA). Streptavidin and pAkt (S473) Ab were from Invitrogen (Carlsbad, CA). Anti-β-actin and ionomycin were from Sigma (St. Louis, MO). Akt 1/2 and PMA were from EMD Biosciences (San Diego, CA). Akt siRNA oligos were from New England Biolabs (Ipswich, MA). Recombinant hIL-2 was obtained through the NIH AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH (Cat. #136), from Hoffman-LaRoche, Inc. Anti-p65 (sc-109x) and anti-IKKγ (sc-8032) were from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-IκBα and phospho-IKKα/β were from Cell Signaling (Danvers, MA). Carm1 antibody was from GenWay (San Diego, CA). Antibodies to Bcl10 and p65 were from Santa Cruz Biotechnology (Santa Cruz, CA). Antibody to K63-linked Ub was from Enzo Life Sciences (Farmingdale, NY).

*T cell lines and transfections* - The D10 T cell clone was maintained in RPMI, with 10% heat-inactivated bovine growth serum (BGS – Hyclone/Thermo Scientific; Waltham, MA) and 25 IU/ml rhIL2. CD4⁺ T cells were isolated from lymph nodes and spleens from 6-12 week-old DO11.10 TCR transgenic mice with the murine T cell purification kit from Miltenyi Biotec (and stimulated in 24-well plates coated with anti-Syrian hamster IgG (Jackson Immunoresearch; West Grove, PA), anti-mouse CD3 (1µg/ml; Invitrogen) and anti-mouse CD28 (5µg/ml; Invitrogen). Th1 cells were differentiated from these cells in the presence of mouse IL-12 (5ng/ml; BD Biosciences), anti-mouse IL-4 (10ng/ml; Biolegend) and rhIL2 (25 IU/ml).

For transfection, T cells were resuspended at 35 x 10⁶ cells/ml in RPMI 1640 without supplements. Cells (0.4 ml of cells in a 0.4-cm cuvette) were electroporated in a Gene-Pulser (Bio-Rad; Hercules, CA) at 250 V and 960 µF, then cultured overnight in 10 ml of complete D10 medium, including IL-2. The next day, live cells were isolated on Lympholyte (Cedarlane Laboratories; Burlington, NC) and re-cultured for 3–4 h in complete D10 medium, excluding IL-2, before stimulation.

*Luciferase assays* - Jurkat T cells were stimulated for six hours with anti-TCR antibody C305. Luciferase assays were then performed as described previously (4).

*Site-directed mutagenesis* – The previously described W80A mutation (15) was made in a murine Akt1 cDNA clone, using the QuikChange system from Stratagene (San Diego, CA). The resulting construct was verified by automated sequencing.

*Cell lysis, SDS-PAGE and western blotting* - Cell lysates were prepared in lysis buffer containing 1% NP-40, 150 mM NaCl, 20 mM Tris-HCl (pH 7.4), and 1 mM EDTA, in addition to protease inhibitors [4-(2-aminoethyl)benzenesulfonyl fluoride (AEBSF), pepstatin A, aprotinin, and leupeptin, all used according to the manufacturer's recommendations (EMD Biosciences) and phosphatase inhibitors (sodium orthovanadate (EMD Biosciences), beta-glycerol phosphate [Sigma]). For analysis of Ub, lysis buffer was also supplemented with 5 mM NEM. Western blotting was carried out as described previously (4). Western blots were developed with SuperSignal West Pico substrate (Pierce/Thermo Scientific) and imaged on a Kodak Image Station 2000R.

*Gene array expression analysis* - T cells were left untreated or pretreated with 20 µM Akti1/2 for 1 hour then stimulated with biotinylated anti-CD3/CD28 and streptavidin for 0, 2, 6 and 12 hrs. Alternatively, T cells were transfected by electroporation with 100 nM Akt Shortcut® siRNA oligos (New England Biolabs). 24 hrs after
transfection cells were stimulated as above. mRNA was isolated with the ArrayGrade mRNA purification kit (SA Biosciences, Frederick, MD). Using the TrueLabeling-AMP Linear RNA amplification kit (SA Biosciences), mRNA was reverse transcribed to obtain cDNA and converted into biotin-labeled cRNA using biotin-16-UTP (Roche Applied Science; Indianapolis, IN) by in vitro transcription. Prior to hybridization, cRNA probes were purified with the ArrayGrade cRNA clean-up kit (SA Biosciences), then hybridized to pretreated Mouse NF-κB Signaling Pathway Microarray OMM-025 (SA Biosciences). Following washing, cRNA binding was detected using alkaline phosphatase-conjugated streptavidin and ECL substrate. Signal was detected with a Kodak Image Station 2000R. The image data were transformed into numerical data and analyzed using GEArray Expression Analysis Suite (SA Biosciences).

Real-time RT-PCR - Total RNA was reverse transcribed using the RT<sup>2</sup> first strand kit (C-03; SA Biosciences). 18s rRNA was chosen as the reference gene for normalization. Real-time PCR was performed with a StepOnePlus Real-Time PCR system (Applied Biosystems; Foster City, CA) using RT<sup>2</sup> SYBR Green/ROX qPCR Master Mixes (SA Biosciences). PCR primers were from SA Biosciences. PCR products were analyzed by melt curve analysis and agarose gel electrophoresis to determine product size and to confirm that no by-products were formed.

Multiplex bead-based and ELISA measurement of cytokines - Secreted levels of seven cytokines in the supernatants of stimulated cells were measured with a custom kit from Bio-Rad, using the Luminex platform. Alternatively, the level of secreted TNF-α in D10 T cell or BMDM cell culture supernatants in some experiments was measured using a commercial mouse TNF-α ELISA kit from BioLegend. Whole heparinized human blood was obtained from the Central Blood Bank (Pittsburgh, PA). Anti-CD3ε (1 µg/ml), anti-CD28 (10 ng/ml) and IL-2 (1:2000 dilution of recombinant human IL-2) were added to whole blood diluted 1:1 in RPMI-1640 and incubated at 37°C for 18 hrs.

Microwell NF-κB DNA binding assay - Binding of nuclear p65/RelA to an NF-κB DNA consensus sequence was measured using a commercially available kit (NF-κB p65 EZ-TFA transcription factor assay (Millipore, Temecula, CA). This method was used as an alternative to electrophoretic mobility shift assay and has been reported to be sensitive and specific (16).

Chromatin Immunoprecipitation - Chromatin immunoprecipitation (ChIP) assays for NF-κB p65 were performed using a ChIP Assay kit (USB; Cleveland, OH) according to the manufacturer’s recommendations. PCR was performed using primers complementary to two sites flanking a ~300-bp fragment of the murine TNF-α promoter between nucleotides -434 and -722 relative to the transcription start site and encoding κB sites 2 and 2a: 5’-AGTCATACGGATTGGGAGAAATCCTG-3’ (forward) and 5’AGTTCTTGGAGGAAGTGGCTG-AAGGCA-3’ (reverse). For IkBa, the primers were: ACTCTTGGGTTCATCCTCAAAAAAGATCATG (forward) and GCCAGTCAGACTAGAAAAAGAAGACTG (reverse). The products were analyzed on a 2% agarose gel.

IKK kinase assay - IKK kinase assays were performed essentially as described previously (4,17). Briefly, the IKK complex was IP’d from unstimulated or stimulated D10 T cells with an antibody to IKKβ. IP’s were then washed into kinase buffer with GST-IκB as a substrate. Reactions were separated on 10% SDS-PAGE gels and imaged by autoradiography.

Collagen-Induced arthritis - Collagen-induced arthritis (CIA) was induced as described previously (18), in accordance with University of Pittsburgh IACUC procedures.

Statistical tests - Results are presented as the mean +/- standard deviation. Where indicated, p values were calculated using a Student’s two-tailed t-test, based on at least three replicate experiments.

RESULTS

We first confirmed which isoforms of Akt are expressed in T cells. Thus, we found that T cells express both Akt1 and Akt2, but do not express detectable levels of Akt3 (Fig. 1A). We next determined whether the inhibitory activity of Akt1/2 is maintained over the time course of T cell stimulation relevant for the experiments performed below. Treatment of a murine T cell clone with Akti 1/2 (10 µM) resulted in long-lasting inhibition of Akt activation (at least twelve hours), as read-out by phosphorylation of S473 (Fig. 1B). To help confirm the specificity of the Akt inhibitor, we tested its efficacy in an NF-κB
reporter assay, using cells transfected with WT Akt or a form of the kinase previously described to be resistant to the effects of Akti 1/2 (15). Thus, consistent with our previous findings (4), Akti 1/2 partially inhibited activation of an NF-κB reporter by TCR stimulation (Fig. 1C). This effect was also pronounced in T cells co-transfected with WT Akt, but not Akt mutated so as to be resistant to the effects of the inhibitor (W80A). Although this and other findings point to Akti 1/2 being a very specific inhibitor of two out of the three mammalian Akt isoforms - Akt1 and Akt2 (14,19) - we were concerned about possible off-target effects. Therefore, we also employed siRNA to knock down the expression of Akt1 and Akt2 in T cells. As shown in Figure 1D, transfection of T cells with oligos specific for Akt1 and Akt2 resulted in significant knock down of Akt protein, peaking at about 24 hours.

To test the hypothesis that Akt is selectively involved in the upregulation of a subset of NF-κB-dependent genes in T cells, we employed targeted microarrays (“NF-κB Signaling Pathway Oligo Array” – see Materials and Methods) specific for 113 genes that are known targets and regulators of NF-κB signaling. Thus, T cells were pre-treated with 10 μM Akti 1/2 for one hour or transfected with Akt-specific siRNA (for 24 hours), then stimulated with anti-CD3/CD28 antibodies, followed by RNA isolation and preparation for array analysis. Stimulation of D10 T cells led to the upregulation of a number of genes represented on the arrays (Fig. 2 and Figs. S1-S4). After pre-treatment with Akti 1/2 or transfection of Akti1/2-specific siRNA oligos only a subset of these genes was impaired in their upregulation (Fig. 2 and Figs. S1-S4). Notable among these were the genes encoding the cytokines TNF-α, LIGHT (Tnfsf14), IL-6, IL-10 and GM-CSF (Csf2), which were similarly affected by both the Akt inhibitor and siRNA treatment (genes highlighted in bold type). Importantly, some known NF-κB targets were not affected by either the Akt inhibitor or siRNA, for example the genes encoding IκBa (Nfkbia) and ICAM1 (Fig. 2 (genes highlighted with asterisks) and Figs. S1,S3).

In order to validate the results obtained with the microarrays, we examined the expression of the genes highlighted above with quantitative RT-PCR. The qRT-PCR analysis confirmed our initial observation that increases in the messages encoding IκBa and ICAM1 were not affected by Akt inhibition or knockdown (Fig. 3A-B). Importantly, these experiments also confirmed that the CD3/CD28-induced expression of the genes encoding TNF-α (Fig. 3C), LIGHT (Fig. 3D), IL-6 (Fig. 3E), IL-10 (Fig. 3F) and GM-CSF (Fig. 3G) were all inhibited by treatment with 10 μM Akti 1/2 (left panels) or transfection with Akti1/2 siRNA oligos (right panels). Thus, modulation of Akt activity or expression indeed results in selective effects on known NF-κB target genes. Given the particularly striking difference between the effects of Akt modulation on upregulation of the genes encoding IκBα vs. TNF-α, we examined these genes more carefully for a specific connection to their transcriptional regulation by NF-κB.

NF-κB is a well-known regulator of TNF-α transcription, through multiple NF-κB-binding sites in the TNF-α promoter (20,21). We performed chromatin immuno-precipitation (ChIP) analysis of the endogenous TNF-α promoter before and after CD3/CD28 stimulation, with or without the inhibitor Akti 1/2. As shown in Figure 4A (left panel), stimulation of D10 T cells led to increased NF-κB p65 binding to the TNF-α promoter. This activity was significantly impaired in the presence of Akti 1/2, with the effects over three experiments quantified in Figure 4A (right panel). To further solidify the link between Akt, NF-κB and gene expression, we performed ChIP analysis for p65 binding to the promoter of the IκB gene (Nfkbia), expression of which was not affected by Akt inhibition (Figs. 2-3). Thus, as shown in Figure 4B, CD3/CD28 stimulation led to increased p65 binding to the IκB promoter, which was not inhibited by Akti 1/2. These results demonstrate that inhibition of Akt1 and Akt2 inhibits transcription from the TNF-α promoter in T cells at least in part through decreased NF-κB DNA binding. However, binding of p65 to the IκB promoter under the same conditions was not affected. Thus the above-described transcriptional differences were due at least in part to direct effects on NF-κB promoter binding.

In order to better understand the selective effects of Akt inhibition/knock-down on NF-κB promoter binding, we further probed the role of Akt in the NF-κB signaling pathway. As shown in Figure 5A, Akti 1/2 significantly (but not completely) inhibited nuclear entry and DNA binding of p65 induced by stimulation with anti-CD3/CD28 antibodies, at least at this two-hour time point. However, when the kinetics of the response were examined, we did observe an eventual increase in p65 nuclear entry and DNA oligo binding at later time points in the presence of
the Akt inhibitor (Fig. 5B), despite the fact that inhibition of Akt activity was maintained (Fig. 1B). Consistent with the altered kinetics of p65 nuclear entry and DNA binding, we found that inhibition of Akt led to a delay, but not absence, of CD3/CD28-induced degradation of IκBα (Fig. 5C). Thus, consistent with previous studies on the selective control of gene expression by different NF-κB-activating receptors (6), Akt-mediated differences in NF-κB kinetics appear to be translated into specific effects on CD3/CD28-mediated gene expression.

We next worked backwards in the NF-κB pathway to better understand where Akt inhibition was impinging on normal NF-κB induction. IκBα degradation requires phosphorylation by the IκB kinase (IKK) complex (5). Indeed, when we measured IKK kinase activity with an in vitro assay, we noted that CD3/CD28 induced IKK activity was impaired in the presence of Akt1/2 (Fig. 6A). The dynamic range of this kinase assay is not particularly large in our experience, which may account for the apparently larger effect on kinase activity, compared with IκB degradation. Activation of the IKK complex requires both phosphorylation of IKKα/β and ubiquitination (Ub) of IKKγ/NEMO. Blotting stimulated T cell lysates with a phospho-specific antibody to IKKα/β revealed little if any difference in magnitude or kinetics of phosphorylation in the presence or absence of the Akt inhibitor (Fig. 6B). However, when we examined K63-linked Ub of IKKγ, we did note effects of the inhibitor. As shown in Figure 6C, anti-CD3/CD28 or PMA/Iono stimulation increased the amount of K63-Ub on IKKγ. Use of Akt1/2 in this assay revealed two differences: a slight, but reproducible, increase in the basal amount of Ub, and a decrease in the induced Ub, particularly at the 30 minute time point. Since CD3/CD28-mediated Ub of IKKγ requires assembly of a multi-protein complex containing Carma1 and Bcl10 (22), we reasoned that formation of this complex might be impaired by Akt inhibition. T cells were stimulated, with or without Akt1/2, and endogenous Bcl10 was IP’d, followed by western blotting for Carma1. Thus, as shown in Figure 5E, stimulation with anti-CD3/CD28 antibodies led to an increase in the amount of Carma1 co-IP’d with Bcl10, and this was severely impaired in the presence of Akt1/2. As with the IKK kinase assay discussed above, the dynamic range of this co-IP assay is rather modest, which likely explains the apparent severity of the inhibition.

The results discussed above suggest that Akt inhibition may have selective effects on cytokine production by effector T cells. To address this further at the protein level, we determined the role of Akt in the secretion of a panel of cytokines known to be made by the D10 T cell clone, using a multiplex bead-based approach. Thus, we stimulated D10 T cells with anti-CD3/CD28 antibodies, in the presence of different concentrations of Akt1/2 (1, 10 or 20 μM), in order to determine the relative sensitivity of different cytokines to the inhibitor. As shown in Figure 7A there was a preferential effect on certain cytokines at lower doses of the compound, especially at lower doses. Interestingly some of the canonical Th2 cytokines, including IL-4, IL-5, and GM-CSF, but not IL-13, appeared to be more resistant to the effects of Akt1/2, relative to IL-6 and especially TNF-α. A comparative analysis, where the data are normalized (Fig. 7B), suggests that these cytokine break down into two classes, with respect to sensitivity to Akt inhibition, resulting in a shift of the dose response curve of approximately one log.

Given the clinical relevance of TNF-α (23), and the complex post-transcriptional control of TNF-α message (24,25), we further assessed the effects of Akt inhibition on TNF-α protein in T cells from different sources. To confirm the results obtained with the multiplex approach in Figure 7, we measured TNF-α secretion with a sensitive ELISA. As shown in Figure 8A, TNF-α secretion by D10 T cells was profoundly inhibited by Akt1/2, consistent with results discussed above. In addition, we used this approach to measure TNF-α production by T cells transfected with siRNA against Akt1 and Akt2. Consistent with the less-than-complete knock-down of Akt (Fig. 1), we observed significant, although not complete, inhibition of TNF-α production. Similar results were observed with polyclonal Th1 T cells, although the overall level of TNF-α production by these cells was lower (Fig. 8B).

Next, we examined the effects of Akt inhibition on production of TNF-α following anti-CD3/CD28 stimulation of whole human blood. Such an assay is often used for identifying the potential clinical utility of small molecule inhibitors of kinases, in the more complex environment of whole blood (26). As shown in Figure 8C, anti-CD3/CD28 stimulation of whole blood resulted in production of TNF-α, presumably mostly from T cells, and this was significantly inhibited by Akt1/2 (white bars).
While there was substantially more TNF-α produced after stimulation of whole blood cultures with PMA and ionomycin, which bypass receptor-proximal signaling pathways, this was not inhibited by Akti 1/2 (Fig. 8C, black bars). This important control helps to confirm the specificity of the Akt inhibitor, and its lack of general toxicity. Finally, we examined the effect of Akt inhibition on antigen-specific TNF-α production by T cells from a mouse model of rheumatoid arthritis. Thus, mice were immunized with type II collagen (CII), and followed for development of joint swelling (18,27). Upon identification of animals with inflammation, draining lymph nodes and spleens were harvested, and cells were re-stimulated in vitro with antigen. As shown in Figure 8D, addition of antigen (CII) to lymph node cultures (white bars) led to increased secretion of TNF-α, compared with unstimulated (no antigen) cultures. This secretion was inhibited by all doses of Akti 1/2 (from 1-20 µM; shaded bars). We also noted significant inhibition by Akti 1/2 of anti-CD3/CD28-stimulated TNF-α production in these cultures of murine lymph node cells (Fig. 8D). Since a recent publication suggested that Akti 1/2 might act in part through inhibition of CaMK (28), we also stimulated T cells in the presence of the potent CaMK inhibitor KN-93; however this compound had no effect on TNF-α production (data not shown), providing additional evidence that Akti 1/2 blocks TNF-α production as a result of inhibition of Akt activity.

DISCUSSION

In this study, we set out to clarify the role of the serine/threonine kinase Akt in CD3/CD28-induced NF-κB activity. Our data are consistent with a model whereby Akt is not a canonical member of the pathway leading from CD3/CD28 to NF-κB, but rather this kinase appears to modulate flux through the pathway. Importantly, these conclusions were based not only on the use of a selective small molecule inhibitor of Akt, but also siRNA-mediated knock-down of Akt1 and Akt2. While earlier gain-of-function studies suggested a role for Akt in regulating the NF-κB pathway during T cell activation (4,17,29-31), the extent and mechanism of Akt involvement in NF-κB activation have not been clear. Our data show for the first time that Akt activity is required for induction of a subset of NF-κB-dependent genes during T cell activation, at least in part through effects on p65/RelA nuclear entry and DNA binding. One of the most consistently and potently inhibited genes was that encoding TNF-α, a particularly relevant target for immune modulation.

Our current model, based on this and previous work (4), is that Akt exerts a quantitative effect upstream of IKK activation, but downstream of CD3 and CD28, resulting in an amplification of the NF-κB response (Fig. 8). Thus, knock-down or small molecule inhibition of Akt dampens, but does not completely impair, NF-κB activity, as read-out by IkBα degradation and p65 nuclear entry. In particular, the assessment of p65 nuclear entry and DNA binding ability (at least to an oligo) revealed a shift in the kinetics of NF-κB activity in the absence of Akt activation. Several groups have elegantly demonstrated that quantitative effects on NF-κB activity can selectively impact the expression of certain NF-κB target genes (7,8,11,32,33), and that this might underlie the observation that different NF-κB-activating stimuli upregulate the expression of distinct subsets of genes. However, this possibility has not previously been addressed with antigen receptor signaling in T or B cells, nor has it previously been ascribed to a single intermediate in a signaling pathway, as we have demonstrated here with Akt.

Working upstream from p65 and IkB, we show that IKK kinase activity is inhibited by Akti 1/2, as are IKKγ/NEMO ubiquitination and CBM complex assembly. However, IKKα/β phosphorylation appears to be unaffected by Akt inhibition. Thus, based on previous work of Lin and colleagues (22), our data point to a defect at - or upstream of - the CBM complex when Akt is inhibited. This conclusion is also consistent with a previous study from our group which demonstrated a requirement for Carma1 expression in mediating the activation of NF-κB by ectopic Akt expression (4). Although these findings point to possible phosphorylation of one or more CBM components by Akt, we have not yet succeeded in identifying a direct target for Akt phosphorylation in the CBM complex. Carma1 is one possibility, since it is known to be regulated by multiple phosphorylation events (34), but Carma1 contains no obvious sites of Akt phosphorylation. This is an important question for future studies to address.

Intriguingly, we noted that upregulation of the gene encoding IkBα was not significantly affected by Akt inhibition or knock-down, consistent with previous observations in other...
systems that IκBα is less sensitive to the overall magnitude and/or duration of NF-κB activity (7). Since IκBα is an important feedback regulator, overall weaker stimulation of the pathway (e.g. in the presence of the Akt inhibitor), coupled with relatively normal upregulation of IκBα, may result in a more dramatic effect on those genes that require the most robust NF-κB activity (such as TNF-α). Thus, our findings are also consistent with previous reports that NF-κB-dependent TNF-α upregulation is relatively sensitive to the levels of NF-κB activity (11). Although T cells are not usually discussed as major producers of TNF-α during autoimmunity, increased production of TNF-α among antigen-specific T cells has been observed in the CIA model (35). In addition, there are a number of other settings in which T cell production of TNF-α has been linked to bone loss associated with estrogen deficiency (36,37). In addition, the presence of TNF-α-producing T cells correlates with disease severity and progression in multiple sclerosis (38,39). Finally, the production of TNF-α by allo-reactive T cells was shown to predict allograft rejection (40).

There continues to be interest in the potential clinical utility of small molecule inhibitors to target inflammation, particularly in the context of high levels of pro-inflammatory cytokines like TNF-α and IL-6. Although protein drugs that neutralize TNF-α have been successful in the treatment of diseases like rheumatoid arthritis (41), these therapies are expensive and difficult to produce and deliver, and their continued use can lead to the development of neutralizing antibodies that negate their efficacy in some patients. For these reasons, a number of small molecule compounds that show promise in inhibiting either the production or action of pro-inflammatory cytokines like TNF-α continue to be actively pursued (42,43). While inhibition of Akt in various settings has so far been disappointing, due to deleterious effects on metabolic pathways, our studies provide proof-of-principle that partial inhibition of the NF-κB pathway may allow for more selective modulation of downstream gene expression.

REFERENCES

1. Uddin, S., Hussain, A., Al-Hussein, K., Plataniats, L. C., and Bhatia, K. G. (2004) Biochem Biophys Res Commun 320, 932-938
2. Gold, M. R. (2003) Trends Immunol 24, 104-108
3. Manning, B. D., and Cantley, L. C. (2007) Cell 129, 1261-1274
4. Narayan, P., Holt, B., Tosti, R., and Kane, L. P. (2006) Mol Cell Biol 26, 2327-2336
5. Ghosh, S., May, M. J., and Kopp, E. B. (1998) Annu Rev Immunol 16, 225-260
6. Smale, S. T. (2010) Cell 140, 833-844
7. Ashall, L., Horton, C. A., Nelson, D. E., Paszek, P., Harper, C. V., Sillitoe, K., Ryan, S., Spiller, D. G., Unitt, J. F., Broomhead, D. S., Kell, D. B., Rand, D. A., See, V., and White, M. R. (2009) Science 324, 242-246
8. Hoffmann, A., Levchenko, A., Scott, M. L., and Baltimore, D. (2002) Science 298, 1241-1245
9. Nelson, D. E., Ihekwaba, A. E., Elliott, M., Johnson, J. R., Gibney, C. A., Foreman, B. E., Nelson, G., See, V., Horton, C. A., Spiller, D. G., Edwards, S. W., McDowell, H. P., Unitt, J. F., Sullivan, E., Grimley, R., Benson, N., Broomhead, D., Kell, D. B., and White, M. R. (2004) Science 306, 704-708
10. Tian, B., Nowak, D. E., and Brasier, A. R. (2005) BMC Genomics 6, 137
11. Werner, S. L., Barken, D., and Hoffmann, A. (2005) Science 309, 1857-1861
12. Cheng, J. Q., Lindsley, C. W., Cheng, G. Z., Yang, H., and Nicosia, S. V. (2005) Oncogene 24, 7482-7492
13. LoPiccolo, J., Granville, C. A., Gills, J. J., and Dennis, P. A. (2007) Anticancer Drugs 18, 861-874
14. Barnett, S. F., DeFeo-Jones, D., Fu, S., Hancock, P. J., Haskell, K. M., Jones, R. E., Kahana, J. A., Kral, A. M., Leander, K., Lee, L. L., Malinowski, J., McAvoy, E. M., Nahas, D. D., Robinson, R. G., and Huber, H. E. (2005) Biochem J 385, 399-408
15. Green, C. J., Goransson, O., Kular, G. S., Leslie, N. R., Gray, A., Alessi, D. R., Sakamoto, K., and Hundal, H. S. (2008) *J Biol Chem* **283**, 27653-27667

16. Shen, Z., Peedikayil, J., Olson, G. K., Siebert, P. D., and Fang, Y. (2002) *Biotechniques* **32**, 1168, 1170-1162, 1174 passim

17. Kane, L. P., Shapiro, V. S. S., Stokoe, D., and Weiss, A. (1999) *Curr Biol* **9**, 601-604

18. Miyamae, T., Marinov, A. D., Sowders, D., Wilson, D. C., Devlin, J., Boudreau, R., Robbins, P., and Hirsch, R. (2006) *J Immunol* **177**, 4758-4762

19. Logie, L., Ruiz-Alcaraz, A. J., Keane, M., Woods, Y. L., Bain, J., Marquez, R., Alessi, D. R., and Sutherland, C. (2007) *Diabetes* **56**, 2218-2227

20. Saccani, S., Pantano, S., and Natoli, G. (2001) *J Exp Med* **193**, 391-396

21. Trede, N. S., Tsytsykova, A. V., Chatila, T., Goldfeld, A. E., and Geha, R. S. (1995) *J Immunol* **155**, 902-908

22. Shambharkar, P. B., Blonska, M., Pappu, B. P., Li, H., You, Y., Sakurai, H., Darnay, B. G., Hara, H., Penninger, J., and Lin, X. (2007) *Embo J* **26**, 1794-1805

23. Bradley, J. R. (2008) *J Pathol* **214**, 149-160

24. Anderson, P., Phillips, K., Stocklin, G., and Kedersha, N. (2004) *J Leukoc Biol* **76**, 42-47

25. Clark, A. (2000) *Arthritis Res* **2**, 172-174

26. Changelian, P. S., Moshinsky, D., Kuhn, C. F., Flanagan, M. E., Munchhof, M. J., Harris, T. M., Doty, J. L., Sun, J., Kent, C. R., Magnuson, K. S., Perregaux, D. G., Sawyer, P. S., and Kudlac, E. M. (2008) *Blood* **111**, 2155-2157

27. Clutter, S. D., Wilson, D. C., Marinov, A. D., and Hirsch, R. (2009) *J Immunol* **182**, 234-239

28. Gilot, D., Giudicelli, F., Lagadic-Gossmann, D., and Fardel, O. (2010) *Chem Biol Interact* **188**, 546-552

29. Jones, R. G., Parsons, M., Bonnard, M., Chan, V. S., Yeh, W. C., Woodgett, J. R., and Ohashi, P. S. (2000) *J Exp Med* **191**, 1721-1734

30. Jones, R. G., Saibil, S. D., Pun, J. M., Elford, A. R., Bonnard, M., Pellegrini, M., Aarya, S., Parsons, M. E., Krawczyk, C. M., Gerondakis, S., Yeh, W. C., Woodgett, J. R., Boothby, M. R., and Ohashi, P. S. (2005) *J Immunol* **175**, 3790-3799

31. Kane, L. P., Andres, P. G., Howland, K. C., Abbas, A. K., and Weiss, A. (2001) *Nature Immunology* **2**, 37-44

32. Hoffmann, A., and Baltimore, D. (2006) *Immunol Rev* **210**, 171-186

33. Lee, T. K., Denny, E. M., Sanghvi, J. C., Gaston, J. E., Maynard, N. D., Hughey, J. J., and Covert, M. W. (2009) *Sci Signal* **2**, ra65

34. Thome, M., and Weil, R. (2007) *Trends Immunol* **28**, 281-288

35. Latham, K. A., Whittington, K. B., Zhou, R., Qian, Z., and Rosloniec, E. F. (2005) *J Immunol* **174**, 3978-3985

36. Cenci, S., Weitzmann, M. N., Roggia, C., Namba, N., Novack, D., Woodring, J., and Pacifici, R. (2000) *J Clin Invest* **106**, 1229-1237

37. Roggia, C., Gao, Y., Cenci, S., Weitzmann, M. N., Toraldo, G., Isaia, G., and Pacifici, R. (2001) *Proc Natl Acad Sci U S A* **98**, 13960-13965

38. Williams, J., Kalkers, N. F., Meilof, J. F., Barkhof, F., van Lier, R. A., and Polman, C. H. (2001) *Neurology* **57**, 1129-1131

39. Shi, N., Kawano, Y., Matsuoka, T., Mei, F., Ishizu, T., Ohyagi, Y., and Kira, J. (2009) *Mult Scler* **15**, 120-123

40. Brehm, M. A., Mangada, J., Markee, T. G., Pearson, T., Daniels, K. A., Thornley, T. B., Welsh, R. M., Rossini, A. A., and Greiner, D. L. (2007) *Blood* **109**, 819-826

41. Taylor, P. C., and Feldmann, M. (2009) *Nat Rev Rheumatol* **5**, 578-582

42. Palladino, M. A., Bahjat, F. R., Theodorakis, E. A., and Moldawer, L. L. (2003) *Nat Rev Drug Discov* **2**, 736-746

43. Karin, M., Yamamoto, Y., and Wang, Q. M. (2004) *Nat Rev Drug Discov* **3**, 17-26
ACKNOWLEDGEMENTS

Supported by NIH/NIGMS grant GM030398 (to L.P.K.). We thank P. Changelian for advice on the whole blood stimulation assay. We are grateful to S. Gaffen for critical reading of the manuscript. Author contributions: J.C. designed and performed experiments and co-wrote the manuscript; B.P. and D.C.W. performed experiments; R.H. provided funding and designed experiments; L.P.K. provided funding, designed experiments and co-wrote the manuscript. Conflicts of interest: The authors declare no competing financial interests.

FIGURE LEGENDS

Figure 1. Validation of Akt inhibition strategies. (A) Expression of Akt isoforms in T cells. Primary murine T cells (1o) or Jurkat T cells (J) were lysed and IP’d with the indicated Akt isoform-specific antibodies, then analyzed by western blotting with a pan-Akt antibody. (B) D10 T cells were stimulated with anti-CD3/CD28 antibodies for the indicated times, in the absence (left panels) or presence (right panels) of Akt1/2. Cell lysates were analyzed by SDS-PAGE and western blotting for phospho-Akt (S473) (upper panels), followed by total Akt (lower panels). (C) Specificity of Akt1/2 effect on NF-κB reporter demonstrated with an inhibitor-resistant Akt allele. Jurkat T cells were transfected with an NF-κB luciferase reporter and the indicated constructs. The next day, cells were stimulated with anti-TCR antibody, followed by determination of luciferase activity. (D) D10 T cells were transfected with siRNA oligos specific for murine Akt1 and Akt2. Lysates were made at the indicated times after transfection and analyzed by SDS-PAGE for total Akt expression (upper panel) or beta-actin, as a loading control (lower panel). Results of the Akt blot are quantified in the right-hand panel.

Figure 2. Selective effects of Akt inhibition or knock-down on NF-κB signature genes. Representative partial heat maps from D10 T cells were stimulated with anti-CD3/CD28 antibodies and RNA was extracted, followed by analysis of expression of NF-κB pathway genes, as described in the Methods. (A) Partial heat map of gene expression changes, with or without treatment with Akt1/2. (B) Partial heat map of gene expression changes, after transfection with control or Akt1/2-specific siRNA.

Figure 3. Quantitative RT-PCR analysis of Akt-dependent genes in the NF-κB pathway. D10 T cells were stimulated with anti-CD3/CD28 antibodies and RNA was extracted, followed by quantitative RT-PCR analysis of the effects of Akt1/2 (left panels) and Akt siRNA (right panels) on selected NF-κB pathway genes – (A) IκBa; (B) ICAM1; (C) TNF-a; (D) TNFSF14 (LIGHT); (E) IL-6; (F) IL-10; (G) CSF2 (GM-CSF). Results are representative of three separate experiments for each panel. Green diamonds: solvent or control siRNA; blue squares: Akt1/2 or Akt1/2-specific siRNA treatment.

Figure 4. Effects of Akt inhibition at the level of NF-κB promoter binding. (A-B) Chromatin immuno-precipitation was performed on the promoters of the genes encoding TNF-α (A) or 1κBα (B), as described in Experimental Procedures, after stimulation of D10 T cells for six hours in the absence or presence of Akt1/2 (10 µM). Left panels - representative ChIP experiments, out of three that were performed for each gene. Right panels - quantitation of ChIP results over three experiments, represented as the average fold stimulation +/- standard deviation, compared with unstimulated cells.

Figure 5. Akt inhibition alters the kinetics of NF-κB activation downstream of CD3/CD28. (A) D10 T cells were stimulated for two hours, as indicated. Nuclear extracts were prepared and analyzed for p65 binding to an NF-κB consensus oligonucleotide (left panel). The right panel contains controls, including a positive control extract, stimulated cell extract analyzed in the presence of a non-labeled competitor oligonucleotide and a negative control (no probe). Results shown are the average fold stimulation +/- standard deviation of three independent experiments. (B) Time-course of NF-κB p65 nuclear entry, with or without Akt1/2 treatment. (C) Effects of Akt inhibition on CD3/CD28 induced 1κBα degradation. D10 T cells were stimulated with anti-CD3/CD28 antibodies, without or with 10 µM Akt1/2. Cells were fixed, permeabilized and stained for intracellular 1κB and flow cytometry.
Figure 6. Akt inhibition alters signaling to NF-κB from CD3/CD28. (A) Lysates were made and IP’d for the IKK kinase complex, using an antibody to IKKγ/NEMO. Kinase assays were performed and run out on SDS-PAGE gels, transferred to PVDF and exposed to x-ray film (top panel). Blots were then probed for IP’d IKKβ (bottom panel). (B) Cell extracts were analyzed by western blotting for phospho-IKKα/β (top panel), with β-actin as a loading control (lower panel). (C) Stimulated D10 cells were lysed and subjected to IP with anti-IKKγ/NEMO antibody. IP’s were washed with RIPA buffer, followed by western blotting with an antibody to K63-linked ubiquitin. (D) Cells were stimulated as indicated and Bcl10 IP’s were blotted for co-IP’d Carma1 (top panel) or for Bcl10 (second panel), as were whole cell lysates (bottom two panels). Results in each part are representative of at least three experiments.

Figure 7. Differential effects of Akt inhibition on T cell cytokine production. (A) D10 T cells were stimulated for 24 hours with anti-CD3/CD28 mAbs in the absence or presence of increasing concentrations of Akti 1/2 (1, 10 and 20 mM). Supernatants were analyzed for the indicated cytokines with a bead-based multiplex system. Results are the average +/- S.D. of triplicate wells, representative of three experiments. *=p<0.05; **=p<0.01; ***=p<0.001. (B) Results for the indicated cytokines were normalized to the starting time point and graphed together.

Figure 8. Requirement for Akt in TNF-α production by T cells from multiple sources. (A-B) Comparison of Akti 1/2 and Akt siRNA effects on TNF-α production. The murine Th2 cell clone D10 (A) or bulk murine Th1 cells (B) were stimulated as indicated, following 30 min. pre-treatment with Akti 1/2 or 24 hour transfection with Akt1/2 siRNA oligos. After 24 hour stimulation, mTNF-α was measured in cell-free supernatants by ELISA. (C) Whole human blood was stimulated with anti-CD3/CD28 Ab’s for 18 hours, followed by analysis of hTNF-α concentration by ELISA. Results shown are the average +/- standard deviation of triplicate wells from a single experiment, representative of four experiments performed with two different donors. (D) Lymph node cells from mice immunized with type II collagen (CII) were re-stimulated in vitro, without (white bars) or with (shaded bars) Akti1/2, in increasing concentrations (1, 10 and 20 µM). Culture supernatant was assayed for TNF-α by ELISA. Results are the average of triplicate points from a single experiment, representative of three that were performed.

Figure 9. Model for the role of Akt in regulating NF-κB-dependent transcription downstream of the TCR and CD28.
Figure 1

A

**IP Ab:**

| Akt1 | Akt2 | Akt3 |
|------|------|------|
| 10   | 10   | 10   |

Blot: Pan-Akt Antibody

B

**Slim:**

- 20'  2h  6h  12h

+ DMSO

+ Akt1/2

Phos-Akt

Total Akt

C

| RLU |
|-----|
| 800 |
| 600 |
| 400 |
| 200 |

Unstim. Anti-TCR

D

**Total Akt**

| 0h | 24h | 48h | 72h |
|-----|-----|-----|-----|
| 1.0 | 0.64| 0.88| 0.94|

β-Actin
Figure 4

A

B
Figure 5

A

Fold Stimulation

2 hr Stim.

Unstim. CD3/CD28 CD3/CD28 + Akt 1/2 Control Competitor - Control

p = 0.041

B

Fold Stimulation

Hrs > Stimulation

Control + Akt 1/2

C

Fold Stimulation

0 hr 0.5 hr 1 hr 2 hr

Control Akt 1/2

Control

Akt 1/2
Figure 6

A

Kinase Assay

IKKβ IPs

B

Phospho-IKKα/β

β-Actin

CD3/CD28 (mins) 0 5 10 30 45 60 P/I

CD3/CD28 (mins) 0 5 10 30 45 60 P/I

C

CD3/CD28 (mins) 0 15 30 P/I

CD3/CD28 (mins) 0 15 30 P/I

Short Exposure

Long Exposure

IKKγ IPs

Anti-Ub (K63) Blot

D

Unstim. CD3/CD28 CD3/CD28 + Akti/1/2 PMA/ionso

Unstim. CD3/CD28 CD3/CD28 + Akti/1/2 PMA/ionso

Bcl10 IPs

Carma1

Bcl10

Lysates
Figure 7

A

IL-4

IL-5

GM-CSF

IL-6

IL-13

TNF-α

B

% Cytokine

[Akt1/2] μM

- 4, GM-CSF
- IL-6/13, TNF-α

by guest on March 23, 2020http://www.jbc.org/Downloaded from
Figure 9

A

TCR/CD3

CD28

Akt

NF-κB Signaling

Time > Stimulation

B

TCR/CD3

CD28

NF-κB Signaling

Time > Stimulation

---

NF-κB Activity

- Akt-dependent genes (e.g. TNF-α, IL-6)
- Akt-independent genes (e.g. IκBα, ICAM1)
Akt fine-tunes NF-κB-dependent gene expression during T cell activation
Jing Cheng, Binh Phong, David C. Wilson, Raphael Hirsch and Lawrence P. Kane

J. Biol. Chem. published online August 23, 2011

Access the most updated version of this article at doi: 10.1074/jbc.M111.259549

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

Supplemental material:
http://www.jbc.org/content/suppl/2011/08/23/M111.259549.DC1